Last reviewed · How we verify
Nab-paclitaxel （neoadjuvant）
Nab-paclitaxel is a protein-bound paclitaxel formulation that stabilizes microtubules to prevent cell division and induce apoptosis in cancer cells.
Nab-paclitaxel is a protein-bound paclitaxel formulation that stabilizes microtubules to prevent cell division and induce apoptosis in cancer cells. Used for Neoadjuvant treatment of breast cancer (primary indication in this trial context), Metastatic breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | Nab-paclitaxel （neoadjuvant） |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | Microtubule stabilizer / Taxane |
| Target | β-tubulin / Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to β-tubulin and stabilizes microtubule structures, preventing their depolymerization and disrupting the mitotic spindle during cell division. The nanoparticle albumin-bound (nab) formulation improves drug delivery and reduces hypersensitivity reactions compared to conventional paclitaxel. In neoadjuvant settings, it is administered before surgery to shrink tumors and improve surgical outcomes.
Approved indications
- Neoadjuvant treatment of breast cancer (primary indication in this trial context)
- Metastatic breast cancer
- Non-small cell lung cancer
- Pancreatic cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea/vomiting
- Alopecia
- Arthralgia/myalgia
Key clinical trials
- Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (PHASE1)
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (PHASE1)
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors (PHASE2, PHASE3)
- A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: